Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of argumenting an immune response in a mammal, and methods of treating a diseases in a mammal utilizing the vaccine compositions.
Type:
Grant
Filed:
March 28, 2019
Date of Patent:
November 10, 2020
Assignees:
PDS Biotechnology Corporation, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE DEPT. OF HEALTH AND HUMAN SERVICES
Inventors:
Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.
Type:
Grant
Filed:
June 13, 2013
Date of Patent:
May 14, 2019
Assignees:
PDS Biotechnology Corporation, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE DEPT. OF HEALTH AND HUMAN SERVICES
Inventors:
Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
Abstract: A polarization-based colposcopy apparatus includes a polarization exchanging beam splitter pair oriented so that s- and p-polarizations are exchanged. An optical flux from a specimen is directed through the pair, and orthogonal components thereof are alternately or selectively coupled to an array detector. The detected images are processed based on image correlations to reveal specimen structures.
Type:
Application
Filed:
April 4, 2013
Publication date:
April 23, 2015
Applicant:
The United States of America, as represented by the Sec. Dept. of Health and Human Services
Inventors:
Amir Gandjbakhche, Victor Chernomordik, Moinuddin Hassan, Alexander Sviridov, Zachary Ulissi, Paul D. Smith, Albert C. Boccara
Abstract: The invention relates to a Bacillus anthracis (B. anthracis) in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield. The disclosure provides a B. anthracis that comprises a genetic modification that inactivates a protease of the M4 family of metallopro teases and a genetic modification that inactivates a protease of the M6 family of metalloproteases. Also provided is a modified B. anthracis comprising such genetic modification transformed with a recombinant molecule encoding a product, as well as methods to prepare and use such B. anthracis.
Type:
Application
Filed:
August 2, 2012
Publication date:
October 23, 2014
Applicant:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SEC, OF DEPT OF HEALTH AND HUMAN SERVICES
Inventors:
Andrei P. Pomerantsev, Stephen H. Leppla
Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.
Type:
Application
Filed:
June 13, 2012
Publication date:
May 15, 2014
Applicants:
Novartis AG, The United States of America, as represented by the Sec., Dept of Health and Human Services
Inventors:
Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong
Abstract: Disclosed are compounds that release nitric oxide, e.g., a compound of Formula (I) wherein R1-10, X, and n are as described herein, which are NSAID derivatives comprising a diazeniumdiolate moiety N2O2?. The compounds are chemopreventive agents with gastric-sparing, analgesic, cardioprotective, and/or anti-inflammatory properties. Also disclosed is a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier. Also disclosed is a method of preventing or treating cancer or treating inflammation or an inflammation-related condition in a mammal comprising administering an effective amount of a compound of the invention to the mammal.
Type:
Application
Filed:
April 24, 2007
Publication date:
July 23, 2009
Applicants:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SEC., DEPT. OF HEALTH AND HUMAN SERVICES, The Governors of the University of Alberta
Inventors:
Carlos A. Velázquez, Joseph E. Saavedra, Larry Keefer, Brett Showalter, Edward E. Knaus